Chemogenomics knowledge-based strategies in drug discovery

Drug News and Perspectives

Volumn 16, Issue 2, 2003, Pages 93-102

  Jacoby, Edgar ^a   Schuffenhauer, Ansgar ^a   Floersheim, Philipp ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

2 DIPROPYLAMINO 8 HYDROXYTETRALIN; 5 METHYLURAPIDIL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; FLESINOXAN; KETANSERIN; PROPRANOLOL; SEROTONIN; SEROTONIN 1A AGONIST; SEROTONIN 2A ANTAGONIST; SEROTONIN AGONIST;

AMINO ACID SEQUENCE; BIOINFORMATICS; DRUG INFORMATION; DRUG STRUCTURE; MOLECULAR DYNAMICS; MOLECULAR RECOGNITION; REVIEW; STRUCTURE ACTIVITY RELATION;

COMPUTATIONAL BIOLOGY; DATABASES, FACTUAL; DRUG DESIGN; GENOMICS; GTP-BINDING PROTEINS; HUMANS; ION CHANNEL GATING; ION CHANNELS; LIGANDS; MODELS, MOLECULAR; RECEPTORS, CELL SURFACE; RECEPTORS, CYTOPLASMIC AND NUCLEAR; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0038270775     PISSN: 02140934     EISSN: None     Source Type: Journal    
DOI: 10.1358/dnp.2003.16.2.829326     Document Type: Review

References (46)

1. Kliewer, S.A., Lehmann, J.M. and Willson, T.M. Orphan nuclear receptors: Shifting endocrinology into reverse. Science 1999, 284:757-60.
2. Murcko, M. and Caron, P. Transforming the genome to drug discovery. Drug Discov Today 2002, 7: 583-4.
3. Wess, G. How to escape the bottleneck of medicinal chemistry. Drug Discov Today 2002, 4: 533-5.
4. Caron, P.R., Mullican, M.D., Mashal, R.D., Wilson, K.P., Su, M.S. and Murcko, M.A. Chemogenomic approaches to drug discovery. Curr Opin Chem Biol 2001, 5: 464-70.
5. Hopkins, A.L. and Groom, C.R. The drugable genome. Nat Rev Drug Discov 2002, 1: 727-30.
6. Stadel, J.M., Wilson, S. and Bergsma, D.J. Orphan G-protein-coupled receptors: A neglected opportunity for pioneer drug discovery. Trends Pharmacol Sci 1997, 18: 430-7.
7. The Gene Ontology Consortium. Gene ontology: Tool for the unification of biology. Nat Genet 2000, 25: 25-9.
8. Enzyme Nomenclature 1992 Academic Press, San Diego, California, ISBN 0-1227164-5; Suppl. 1: Eur J Biochem 1994, 223: 1-5; Suppl. 2: Eur J Biochem 1995, 232: 1-6; Suppl. 3: Eur J Biochem 1996, 237: 1-5; Suppl. 4: Eur J Biochem 1997, 250: 1-6; Suppl. 5: Eur J Biochem 1999, 264: 610-50.
9. Enzyme Nomenclature 1992 Academic Press, San Diego, California, ISBN 0-1227164-5; Suppl. 1: Eur J Biochem 1994, 223: 1-5; Suppl. 2: Eur J Biochem 1995, 232: 1-6; Suppl. 3: Eur J Biochem 1996, 237: 1-5; Suppl. 4: Eur J Biochem 1997, 250: 1-6; Suppl. 5: Eur J Biochem 1999, 264: 610-50.
10. Enzyme Nomenclature 1992 Academic Press, San Diego, California, ISBN 0-1227164-5; Suppl. 1: Eur J Biochem 1994, 223: 1-5; Suppl. 2: Eur J Biochem 1995, 232: 1-6; Suppl. 3: Eur J Biochem 1996, 237: 1-5; Suppl. 4: Eur J Biochem 1997, 250: 1-6; Suppl. 5: Eur J Biochem 1999, 264: 610-50.
11. Enzyme Nomenclature 1992 Academic Press, San Diego, California, ISBN 0-1227164-5; Suppl. 1: Eur J Biochem 1994, 223: 1-5; Suppl. 2: Eur J Biochem 1995, 232: 1-6; Suppl. 3: Eur J Biochem 1996, 237: 1-5; Suppl. 4: Eur J Biochem 1997, 250: 1-6; Suppl. 5: Eur J Biochem 1999, 264: 610-50.
12. Enzyme Nomenclature 1992 Academic Press, San Diego, California, ISBN 0-1227164-5; Suppl. 1: Eur J Biochem 1994, 223: 1-5; Suppl. 2: Eur J Biochem 1995, 232: 1-6; Suppl. 3: Eur J Biochem 1996, 237: 1-5; Suppl. 4: Eur J Biochem 1997, 250: 1-6; Suppl. 5: Eur J Biochem 1999, 264: 610-50.
13. Enzyme Nomenclature 1992 Academic Press, San Diego, California, ISBN 0-1227164-5; Suppl. 1: Eur J Biochem 1994, 223: 1-5; Suppl. 2: Eur J Biochem 1995, 232: 1-6; Suppl. 3: Eur J Biochem 1996, 237: 1-5; Suppl. 4: Eur J Biochem 1997, 250: 1-6; Suppl. 5: Eur J Biochem 1999, 264: 610-50.
14. The IUPHAR Committee on Receptor Nomenclature and Drug Classification. The IUPHAR compendium of receptor characterization and classification, 2nd edition, IUPHAR Media 2000.
15. Horn, F., Vriend, G. and Cohen, F.E. Collecting and harvesting biological data: The GPCRDB & NucleaRDB databases. Nucleic Acids Res 2001, 29: 346-9.
16. Le Novère, N. and Changeux, J.-P. LGICdb: The ligand-gated ion channel database. Nucleic Acids Res 2001, 29: 294-5.
17. MDL Drug Data Report, MDL ISIS/HOST software, MDL Information Systems, Inc.
18. Derwent World Drug Index, MDL ISIS/HOST software, Derwent Information Ltd.
19. Comprehensive Medicinal Chemistry (CMC-3D) database, MDL ISIS/HOST software. CMC is an updated electronic version of Comprehensive Medicinal Chemistry, Pergamon Press 1990, Vol. 6.
20. IDdb - Investigational Drugs database, Current Drugs Ltd.
21. PharmaProjects, PJB Publications Ltd.
22. Nishioka, T., Sumi, K. and Oda, J. Finding lead structures from amino acid sequence similarities of target proteins. In: Probing Bioactive Mechanism. P.S. Magee, D.R. Henry and J.H. Block (Eds.). American Chemical Society, New York 1989, 105-22.
23. Schuffenhauer, A., Zimmermann, J., Stoop, R., van der Vyver, J.J., Lecchini, S. and Jacoby, E. An ontology for pharmaceutical ligands and its application for library design and in silico screening. J Chem Inf Comput Sci 2002, 42: 947-55.
24. Cheek, S., Zang, H. and Grishin, N.V. Sequence and structure classification of kinases. J Mol Biol 2002, 320: 855-81.
25. Robinson, D.R., Wu, Y.-M. and Lin, S.-F. The protein tyrosine kinase family of the human genome. Oncogene 2000, 19: 5548-57.
26. Frye, S.V. Structure-activity relationship homology (SARAH): A conceptual framework for drug discovery in the genomic era. Chem Biol 2001, 6: R3-7.
27. Jacoby, E. A novel chemogenomics knowledge-based ligand design strategy - application to G protein-coupled receptors. Quant Struct Act Relat 2001, 20: 115-23.
28. Van Rhee, A.M. and Jacobson, K.A. Molecular architecture of G-protein-coupled receptors. Drug Develop Res 1996, 37: 1-38.
29. Strader, C.D., Sigal, I.S., Register, R.B., Candelore, M.R., Rands, E. and Dixon, R.A. Identification of residues required for ligand binding to the beta-adrenergic receptor. Proc Natl Acad Sci USA 1987, 84: 4384-8.
30. Ames, R.S., Sarau, H.M., Chambers, J.K. et al. Human urotensin-II is a potent vasoconstrictor and agonist for the orphan receptor GPR14. Nature 1999, 40: 282-6.
31. Shimomura, Y., Mori, M., Sugo, T. et al. Isolation and identification of melanin-concentrating hormone as the endogenous ligand of the SLC-I receptor. Biochem Biophys Res Commun 1999, 261: 622-6.
32. Pfáffli, P., Neumann, P., Swoboda, R. and Stutz, P. Preparation of ergoline derivatives for pharmaceutical use. PCT Int Appl 1998, WO 9854183.
33. Neumann, P., Pfáffli, P., Seiler, M.-P. and Swoboda, R. Preparation of benzo[g]quinoline derivatives as selective antagonists at somatostatin sstl receptors. PCT Int Appl 1997, WO9703054.
34. Mirzadegan, T., Diehl, E, Ebi, B. et al. Identification of the binding site for a novel class of CCR2b chemokine receptor antagonists binding to a common chemokine receptor motif within the helical bundle. J Biol Chem 2000, 275: 25562-71.
35. Schuffenhauer, A., Floersheim, P., Acklin, P. and Jacoby, E. Similarity metrics for ligands reflecting the similarity of the target proteins. J Chem Inf Comput Sci 2003, 43: 391-405.
36. Sheridan, R.P. and Kearsley, S.K. Why do we need so many chemical similarity search methods? Drug Discov Today 2002, 4: 903-11.
37. Jacoby, E., Fauchère, J.-L., Raimbaud, E., Ollivier, S., Michel, A. and Spedding, M. A three binding site hypothesis for interactions of ligands with monoamine G protein-coupled receptors: Implications for combinatorial ligand design. Quant Struct-Act Relat 1999, 18: 561-72.
38. Martin, G.R., Hoyer, D., Villalon, C., Göther, M. and Middlemiss, D.N. 5-hydroxytrytamine receptors. In: The IUPHAR Compendium of Receptor Characterization and classification, 2nd edition. IUPHAR Media 2000, 233-51.
39. Patchett, A.A. and Nargund, R.P. Privileged structures - an update. In: Annual Reports in Medicinal Chemistry, Vol. 35. G.L. Trainor (Ed.). Academic Press: San Diego 2000, 289-98.
40. Klabunde, T. and Hessler, G. Drug design strategies for targeting G-protein coupled receptors. ChemBioChem 2002, 3: 928-44.
41. Michalovich, D., Overington, J. and Fagan, R. Protein sequence analysis in silico: Application of structure-based bioinformatics to genomic initiatives. Curr Opin Pharmacol 2002, 2: 574-80.
42. Crossley, R. and Kenny, B. G-protein coupled receptors: Understanding family activity relationships in drug design. GOR 2002, 4: 20-2.
43. Drews, J. Genomic sciences and the medicine of tomorrow. Nat Biotechnol 1996, 14: 1516-8.
44. Zanders, E.D., Bailey D.S., and Dean, P.M. Probes for chemical genomics by design. Drug Discov Today 2002, 7: 711-8.
45. Jacoby, E., Davies, J. and Blommers M.J.J. Design of small molecule libraries for NMR screening and other applications in drug discovery. Curr Topics Med Chem 2002, 2: 1279-91.
46. Böhm, H.J., Boehringer, M., Bur, D. et al. Novel inhibitors of DNA gyrase: 3D structure-based biased needle screening, hit validation by biophysical methods, and 3D guided optimization. A promising alternative to random screening. J Med Chem 2000, 43: 2664-74.